Immutep (IMMP) Asset Writedowns and Impairment (2015 - 2026)
Immutep's (IMMP) quarterly Asset Writedowns and Impairment came in at $2.2 million in Q2 2026, up 42387.65% quarter-over-quarter from $5160.0 in Q2 2015.
Powered by 
Analysis
Immutep (IMMP) Asset Writedowns and Impairment (2015 - 2026) Analysis & Trends
Immutep (IMMP) has reported Asset Writedowns and Impairment for 2 consecutive years, with $2.2 million the latest figure, recorded in Q2 2026.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Amgen | 236.37 Bn | 222.38 Bn | 7.24 Bn |
| 2 | Gilead Sciences | 187.38 Bn | 184.12 Bn | 6.22 Bn |
| 3 | Vertex Pharmaceuticals | 138.36 Bn | 130.51 Bn | 2.84 Bn |
| 4 | Regeneron Pharmaceuticals | 85.09 Bn | 77.10 Bn | 3.93 Bn |
| 5 | Argenx Se | 63.93 Bn | 58.75 Bn | 1.37 Bn |
| 6 | Moderna | 58.07 Bn | 52.94 Bn | 52.00 Mn |
| 7 | Alnylam Pharmaceuticals | 35.59 Bn | 32.28 Bn | 992.69 Mn |
| 8 | Biogen | 32.63 Bn | 31.34 Bn | 1.96 Bn |
| 9 | Insmed | 27.57 Bn | 26.41 Bn | 358.27 Mn |
| 10 | Immutep | 52.57 Mn | 52.57 Mn | - |